Hypertension in pregnancy: New recommendations for managemen

Current Hypertension Reports

Volumn 1, Issue 6, 1999, Pages 529-539

  Shear, Roberta ^a   Leduc, Line ^a   Rey, Evelyne ^a   Moutquin, Jean Marie ^b  

^a UNIVERSITY OF MONTREAL   (Canada)

^b UNIVERSITÉ DE SHERBROOKE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BLOOD PRESSURE; FEMALE; HUMAN; HYPERTENSION; PHYSIOLOGY; PREGNANCY; PREGNANCY COMPLICATION; TREATMENT OUTCOME;

BLOOD PRESSURE; FEMALE; HUMANS; HYPERTENSION; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; TREATMENT OUTCOME;

EID: 0033291394     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-996-0026-7     Document Type: Article

References (96)

1. National High Blood Pressure Education Program: Working group on high blood pressure in pregnancy. Am J Obstet Gynecol 1990, 163:1689-1712.
2. Harm K, Rath W, Hertig E, et al.: Maternal hemolysis, elevated liver enzymes, low platelets count and neonatal income. Am J Perinatol 1995, 12:1-6.
3. Rey E, Couturier A: The prognosis of women with chronic hypertension. Am J Obstet Gynecol 1994, 171:410-416.
4. Helewa ME, Burrows RF, Smith J, et al.: Report of the Canadian Hypertension Society Consensus Conference: definition, evaluation and classification of hypertensive disorders in pregnancy. Can Med Assoc J 1997, 157:715-725.
5. Moutquin JM, Rainville C, Giroux L, et al.: A prospective study of blood pressure in pregnancy: prediction of preeclampsia. Am J Obstet Gynecol 1985, 151:191-196.
6. Ness RB, Roberts JM: Heterogenous causes constituting the single syndrome of preeclamsia: a hypothesis and its implications. Am J Obstet Gynecol 1996, 175:1366-1370.
7. Massé J, Forest JC, Moutquin JM, et al.: A prospective study of several potential markers for early detection of development of preeclampsia. Am J Obstet Gynecol 1993, 169:501-508.
8. Pouliot L, Forest JC, Moutquin JM, et al.: Platelet angiotensin II binding sites and early detection of preeclampsia. Obstet Gynecol 1998, 91:591-595.
9. Endresen MJ, Tosti E, Lorentzen B, et al.: Sera of preeclampsia women are not cytotoxic to endothelial cells in culture. Am J Obstet Gynecol 1995, 172:196-100.
10. O'Brien TF: Predicting preeclampsia. Obstet Gynecol 1990, 75:445-452.
11. Irion O, Massé J, Forest JC, et al.: Prediction of preeclampsia, low birthweight for gestation and prematurity by uterine artery blood flow velocity waveforms analysis in low risk nulliparas. Br J Obstet Gynaecol 1998, 105:422-429.
12. Chesley LC, Cooper DW: Genetics of hypertension in pregnancy: possible single gene control of preeclampsia and eclampsia in the descendants of eclamptic women. Br J Obstet Gynaecol 1986, 93:898-906.
13. Cooper DW, Hill JA, Chesley LC, et al.: Genetic control of susceptibility to eclampsia and miscarriage. Br J Obstet Gynaecol 1988, 95:644-653.
14. Thornton JG, Macdonald AM: Twin mothers pregnancy hypertension and preeclampsia. Br J Obstet Gynaecol 1999, 106:570-575.
15. Ward K, Hata A, Jeunemaitre X, et al.: A molecular variant of antiogensinogen associated with preeclampsia. Nature Genetics 1993, 4:59-61.
16. Arngrimson R, Purandare S, Connor M, et al.: Angiotnesinogen: a candidate gene involved in preeclampsia? Nature Genetics 1993, 4:114-115.
17. Wilton AN, Kaye JA, Guo G, et al.: Is angiotensinogen a good candidate gene for preeclampsia? Hypertens Preg 1995, 14:251-260.
18. Folgero T, Storbakk N, Torbergsen T, et al.: Mutations in mitochondrial transfert ribonucleic acid genes in preeclampsia. Am J Obstet Gynecol 1996, 174:1626-1630.
19. Humphrey KE, Jarrison GA, Cooper DW, et al.: HLA-G deletion polymorphism and preeclamsia/eclampsia. Br J Obstet Gynaecol 1995, 102:707-710.
20. Arngrimsson R, Geirsson RT, Cooke A, et al.: Renin gene restrictions fragment length polymorphisms do not show linkage with preeclampsia and eclampsia. Acta Obstet Gynecol Scand 1994, 73:10-13.
21. Schiff E, Friedman SA, Sibai BM, et al.: Plasma and placental calcitonin gene-related peptide in pregnancies complicated by severe preeclampsia. Am J Obstet Gynecol 1995, 173:1405-409.
22. Morgan L, Crawshaw S, Bajer PN, et al.: Function and genetic studies of the angiotensin II type 1 receptor in preeclampsia and normotensive pregnant woment. J Hypertens 1997, 15:1389-1396.
23. Chen G, Wilson R, Wang SH, et al.: Tumor necrosis factor-alpha (TNF-alpha) gene polymorphism and expression in preeclampsia. Clin Exp Immunol 1996, 104:154-159.
24. Dekker GA, De Vries JIP, Doelitzsch PM, et al.: Underlying disorders associated with severe early-onset preeclampsia. Am J Obstet Gynecol 1995, 173:1042-1048.
25. Arias F, Romero R, Joist H, et al.: Thrombophilia: a mechanism of disease in women with adverse pregnancy outcome and thrombotic lesions in the placenta. J Mater Fetal Med 1998, 7:277-286.
26. Kupferminc MJ, Eldor A, Steinman N, et al.: Increased frequency of genetic thrombophilia in women with complications of pregnancy N Engl J Med 1999, 340:9-13.
27. Bertina R, Koelman B, Koster T, et al.: Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994, 369:64-67.
28. Bonnar J, Green R, Norris L: Inherited thrombophilia and pregnancy: the obstetric perspective. Sem Thromb Hemost 1998, 24:49-53.
29. Dizon-Thownson DS, Nelson LM, Easton K, et al.: The Factor V Leiden mutation may predispose women to severe preeclampsia. Am J Obstet Gynecol 1996, 175:902-925.
30. Grandone E, Margaglione M, Colaizzo D, et al.: Factor V Leiden, CÆT MTHFR polymorphism and genetic susceptibility to preeclampsia. Thromb Haemost 1997, 77:1052-1054.
31. Wiener-Megnazi Z, Ben-Shlomo I, Goldberg Y, et al.: Resistance to activated protein C and the Leiden mutation: high prevalence in patients with abruptio placentae. Am J Obstet Gynecol 1998, 179:1565-1567.
32. Grandone E, Margaglione M, Colaizzo D, et al.: Factor V Leiden is associated with repeated and recurrent fetal loss. Thromb Haemost 1997, 77:822-824.
33. Ridker PM, Miletich JP, Buring JE, et al.: Factor V Leiden mutation as a risk factor for recurrent pregnancy loss. Ann Intern Med 1998, 128:1000-1003.
34. Grandone E, Margaglione M, Colaizzo D, et al.: Prethrombotic genetic risk factors and the occurrence of gestational hypertension with or without proteinuria. Thromb Haemost 1990, 81:349-352.
35. Sohda S, Arinami T, Hamada H, et al.: Methylenetetrahydrofolate reductase polymorphism and preeclampsia. J Med Genet 1997, 34:525-526.
36. Goddijn-Wessel TA, Wouters MG, Van De Molen EF, et al.: Hyperhomocysteinema: a risk factor for placental abruption or infarction. Eur J Obstet Gynecol Reprod Biol 1996, 66:23-29.
37. Van Der Put NM, Steegers-Theunissen R P, Frosst P, et al.: Mutated methylenetetrahydrofolate reductase as a risk factor for spina bifida. Lancet 1995, 346:1070-1071.
38. Powers RW, Evans RW, Majors AK, et al.: Plasma homocysteine concentration is increased in preeclampsia and is associated with evidence of endothelial activation. Am J Obstet Gynecol 1998, 179:1605-1611.
39. Laivuori H, Kaaja R, Turpeinen U, et al.: Plasma homocysteine levels elevated and inversely related to insulin sensitivity in preeclampsia. Obstet Gynecol 1999, 93:489-493.
40. Leeda M, Rijozi N, De Vries JIP, et al.: Effects of folic acid and vitamin B6 supplementation on women with hyperhomocysteinemia and a history of preeclampsia or fetal growth restriction. Am J Obstet Gynecol 1998, 170:135-139.
41. Kahn SR: Severe preeclampsia associated with coinheritance of Factor V Leiden mutation and protein S deficiency. Obstet Gynecol 1998, 91:812-814.
42. De Vries JI, Dekker GA, Huijgens PC, et al.: Hyperhomocysteinaemia and protein S deficiency in complicated pregnancies. Br J Obstet Gynaecol 1997, 104:1248-1254.
43. Cowchock S: Treatment of antiphospholipid syndrome in pregnancy Lupus 1998, 7:S95-S97.
44. Moutquin JM, Garner PR, Burrows R F, et al.: Report of the Canadian Hypetension Society Consensus Conference 2: nonpharmacologic management and prevention of hypertensive disorders in pregnancy. Can Med Assoc J 1997, 157:907-919.
45. Rey E, Le Lorier J, Burgess E, et al.: Report of the Canadian Hypertensive Society Consensus Conference 3: pharmacologic treatment of hypertension disorders in pregnancy Can Med Assoc J 1997, 157:1245-1254.
46. Helewa M, Heaman M, Robinson MA, et al.: Community-based home care program for the management of preeclampsia: an alternative Can Med Assoc J 1993, 149:829-834.
47. Josten LE, Savik K, Mullet SE, et al.: Bed rest compliance for women with pregnancy problems. Birth 1996, 22:1-12.
48. Crowther CA, Bouwmeester AM, Ashurst HM: Does admission to hospital for bed rest prevent progression or improve fetal outcome in pregnancy complicated by non-proteinuric hypertension? Br J Obstet Gynaecol 1992, 99:13-18.
49. Chan FY, Pun TC, Lam C, et al.: Pregnancy screening by uterine artery Doppler velocimetry: which criterion performs best? Obstet Gynecol 1995, 85:596-602.
50. Mires GJ, Williams FLR, Leslie J, et al.: Assessment of uterine arterial notching as a screening test for adverse pregnancy outcome. Am J Obstet Gynecol 1998, 179:1317-1323.
51. Van Asselt K, Gudmundsson S, Lindqvist P, et al.: Uterine and umbilical artery velocimetry in pre-eclampsia. Acta Obstet Gynecol Scand 1998, 77:614-619.
52. Wang KG, Chen CP, Yang JM, et al.: Impact of reverse enddiastolic flow velocity in umbilical artery on pregnancy outcome after the 28th gestational week. Acta Obstet Gynecol Scand 1998, 77:527-531.
53. Omtzigt AMW J, Reuwer PJH M, Bruinse HW: A randomized controlled trial on the clinical value of umbilical Doppler velocimetry in antenatal care. Am J Obstet Gynecol 1994, 170:625-634.
54. Nielson JP, Alfirevic Z: Doppler ultrasound for fetal assessment in high-risk pregnancies. In Cochrane Collaborations: Cochrane Database of Systematic Reviews: Pregnancy and Childbirth Module. Oxford: Update Software; 1999, 2.
55. Collins R, Duley L: Any antihypertensive therapy for pregnancy hypertension. In Cochrane Collaborations: Cochrane Database of Systematic Reviews: Pregnancy and Childbirth Module. Oxford: Update Software; 1995.
56. Magee LA, Ornstein MP, Von Dadelszen P: Fortnightly review: management of hypertension in pregnancy. BMJ 1999, 318:1332-1336.
57. Steyn DW, Odendaal HJ: Randomised controlled trial of ketanserin and aspirin in prevention of pre-eclampsia. Lancet 1997, 350:1267-1271.
58. Gruppo di Studio Ipertensione in Gravidanza: Nifedipine versus expectant management in mild to moderate hypertension in pregnancy Br J Obstet Gynaecol 1998, 105:718-722.
59. Tamas P, Csermely T, Ertl T, et al.: Calcium dobesilate lowers the blood pressure in mild to moderate midtrimester hypertension: a pilot study. Gynecol Obstet Invest 1999, 47:210-213.
60. CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group: A randomized trial of low-dose aspirin for the prevention and treatment of preeclampsia among 9364 pregnant women. Lancet 1994, 343:619-629.
61. Golding J, on behalf of the Jamaica Low-Dose Aspirin Study Group: A randomized trial of low-dose aspirin for primiparae in pregnancy Br J Obstet Gynaecol 1998, 105:293-299.
62. Rotchell YE, Cruickshank JK, Phillips GM, et al.: Barbados Low-Dose Aspirin in Pregnancy (BLASP): a randomized trial for the prevention of preeclampsia and its complications. Br J Obstet Gynaecol 1998, 105:286-292.
63. ECPPA (Estudo Collaborative Para Prevencao da Pre-eclampsia com Aspirina) Collaborative Group: Randomised trial of low-dose aspirin for the prevention of maternal and fetal complications in high risk pregnant women. Br J Obstet Gynaecol 1996, 103:39-47.
64. Caritis SN, Sibai BM, Hauth J, et al.: Low-dose aspirin therapy for the prevention of preeclampsia in high-risk women. N Engl J Med 1998, 338:701-705.
65. Dumont A, Flahault A, Beaufils M, et al.: Effect of aspirin in pregnant women is dependent on increase in bleeding time. Am J Obstet Gynecol 1999, 180:135-140.
66. Bower SJ, Harrington KF, Schuchter K, et al.: Prediction of preeclampsia by abnormal uterine Doppler ultrasound and modification by aspirin. Br J Obstet Gynaecol 1996, 103:625-629.
67. Belizan JM, Villar J, Gonzalez L, et al.: Calcium supplementation to prevent hypertensive disorders of pregnancy. N Engl J Med 1991, 325:1399-1405.
68. Levine RJ, Hauth JC, Curet LB, et al.: Trial of calcium to prevent preeclampsia. N Engl J Med 1997, 337:69-76.
69. Waisman GD, Mayorgoi LM, Camera MI, et al.: Magnesium plus nifedipine: potentiation of hypotensive effect in preeclampsia? Am J Obstet Gynecol 1988, 159:308-309.
70. Duley L, Henderson-Smart DJ: Drugs for rapid treatment of very high blood pressure during pregnancy. In Cochrane Collaborations: Cochrane Database of Systematic Reviews: Pregnancy and Childbirth Module. Oxford: Update Software; 1999, 3.
71. Mabie WC, Gonzalez AR, Sibai SM, et al.: A comparative trial of labetalol and hydralazine in the acute management of severe hypertension complicating pregnancy. Obstet Gynecol 1987, 70:328-333.
72. Matins-Costa S, Ramos JG, Barros E, et al.: Randomized, controlled trial of hydralazine versus nifedipine in preeclamptic women with acute hypertension. Clin Exp Hypertens 1992, 11:25-44.
73. Bolte AC, Van Eyck J, Kanhai HH, et al.: Ketanserin versus dihydralazine in the management of severe early-onset preeclampsia: maternal outcome. Am J Obstet Gynecol 1999, 80(pt 1):371-377.
74. Wacker J, Werner P, Walter-Sack I, et al.: Treatment of hypertension in patients with pre-eclampsia: a prospective parallel-group study comparing digydralazine with urapidil. Nephrol Dial Transplant 1998, 13:318-325.
75. Kumar N, Batra YK, Bala I, et al.: Nifedipine attenuates the hypertensive response to tracheal intubation in pregnancyinduced hypertension. Can J Anaesth 1993, 40:329-333.
76. Ramanathan J, Sibai BM, Mabie WC, et al.: The use of labetalol for attenuation of the hypertensive response to endotracheal intubation in preeclampsia. Am J Obstet Gynecol 1988, 159:650-654.
77. Ramanathan J, Coleman P, Sibai BM: Anesthetic modification of hemodynamic and neuroendocrine stress responses to cesarean delivery in women with severe preeclampsia. Anesth Analg 1991, 73:772-779.
78. The Eclampsia Trial Collaborative Group: Which anticonvulsant for women with eclampsia? Evidence from the Collaborative Eclampsia Trial. Lancet 1995, 345:1455-1463.
79. Coetzee EJ, Dommisse J, Anthony J: A randomised controlled trial of intravenous magnesium sulphate versus placebo in the management of women with severe pre-eclampsia. Br J Obstet Gynaecol 1998, 105:300-303.
80. Lucas MJ, Leveno KJ, Cunningham FG: A comparison of magnesium sulfate with phenytoin for the prevention of preeclampsia. N Engl J Med 1995, 333:201-205.
81. Duley L, Gulmezoglu AM, Henderso-Smart DJ: Anticonvulsants for preeclampsia. In Cochrane Collaborations: Cochrane Database of Systematic Reviews: Pregnancy and Childbirth Module. Oxford: Update Software; 1999, 2.
82. Burrows RF, Burrows EA: The feasibility of a control population for a randomized control trial of seizure prophylaxis in the hypertensive disorders of pregnancy. Am J Obstet Gynecol 1995, 173:929-935.
83. Clark SL, Cotton DB: Clinical indications for pulmonary artery catheterization in the patient with severe preeclampsia. Am J Obstet Gynecol 1988, 158:453-458.
84. Clark SL, Greenspoon JS, Aldahl D, et al.: Severe preeclampsia with persistant oliguria: management of hemodynamic subsets. Am J Obstet Gynecol 1986, 154:490-494.
85. Benedetti TJ, Kates R, Williams V: Hemodynamic observations in severe preeclampsia complicated by pulmonary edema. Am J Obstet Gynecol 1985, 152:330-334.
86. Belfort MA, Anthony J, Saade GR, et al.: The oxygen consumption/oxygen delivery curve in severe preeclampsia: evidence for a fixed oxygen extraction state. Am J Obstet Gynecol 1993, 169:1448-1455.
87. Hayes MA, Timmins AC, Yau EHS, et al.: Elevation of systemic oxygen delivery in the treatment of critically ill patients. N Engl J Med 1994, 330:1717-1722.
88. Gattinoni L, Brazzi L, Pelosi P, et al.: A trial of goal-oriented hemodynamic therapy in critically ill patients. N Engl J Med 1995, 333:1025-1032.
89. Sibai BM, Mercer BM, Schiff E, et al.: Aggressive versus conservative management of severe preeclampsia at 28 to 32 weeks' gestation: a randomized controlled trial. Am J Obstet Gynecol 1994, 171:818-822.
90. Odendaal HJ, Pattinson RC, Bam R, et al.: Aggressive or expectant management for patients with severe preeclampsia between 28-34 weeks' gestation: a randomized controlled trial. Obstet Gynecol 1990, 76:1070-1075.
91. Fenakel K, Fenakel G, Appelman Z, et al.: Nifedipine in the treatment of severe preeclampsia. Obstet Gynecol 1991, 77:331-337.
92. Schiff E, Friedman SA, Sibai BM: Conservative management of severe preeclampsia remote from term. Obstet Gynecol 1994, 84:626-630.
93. Schiff E, Friedman SA, Kao L, et al.: The importance of urinary protein excretion during conservative management of severe preeclampsia. Am J Obstet Gynecol 1996, 175:1313-1316.
94. Chesley SC, Annitto JE, Cosgrove RA: The remote prognosis of eclamptic women: sixth periodic report. Am J Obstet Gynecol 1976, 124:446-459.
95. Sibai BM, Sarinoglu C, Mercer BM: Eclampsia VII: pregnancy outcome after eclampsia and long-term prognosis. Am J Obstet Gynecol 1992, 166:1757-1763.
96. Jonsdottir LS, Arngrimsson R, Geirsson RT, et al.: Death rates from ischemic heart disease in women with a history of hypertension in pregnancy Acta Obstet Gynecol Scand 1995, 74:772-776.